Original articleIntravitreal triamcinolone acetonide for diabetic diffuse macular edema1 2: Preliminary results of a prospective controlled trial☆,
Section snippets
Patients and methods
The protocol was approved by the Institutional Review Board of the Hôpital Saint-Louis, Paris, France. Patients were recruited and enrolled at the Diabetic Retinopathy Unit of the Lariboisière Hospital in Paris.
Results
Between November 2001 and September 2002, 17 patients fulfilled the inclusion criteria and agreed to participate in the study. Two were excluded because of an IOP rise exceeding 15 mmHg after 1 month of treatment with topical 0.1% dexamethasone. Therefore, 15 patients (30 eyes) were included in the study. In this preliminary report, we give the results for the 12 patients (5 males and 7 females) who had a follow-up of at least 3 months. Seven of them were followed up for 6 months.
The mean (±
Discussion
The preliminary results of this prospective controlled study demonstrate the efficacy of one intravitreal injection of TA in reducing macular thickening due to refractory diffuse diabetic ME, at least in the short term. In all injected eyes, we indeed observed, compared with control eyes, a dramatic anatomic improvement in diabetic ME that had been resistant to all previous treatments (Fig 2). This improvement occurred as soon as 1 month after injection. These results confirm those previously
References (28)
- et al.
Visual impairment in diabetes
Ophthalmology
(1984) - et al.
Modified grid laser photocoagulation for diffuse diabetic macular edemalong-term visual results
Ophthalmology
(1991) - et al.
Intravitreal triamcinolone for uveitic cystoid macular edemaan optical coherence tomography study
Ophthalmology
(2001) - et al.
Intravitreal triamcinolone for refractory diabetic macular edema
Ophthalmology
(2002) Diabetic macular edemaa review
Ophthalmology
(1986)- et al.
Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection
Ophthalmology
(2003) - et al.
Twin study on ocular pressure after topical dexamethasone. 1. Frequency distribution of pressure response
Am J Ophthalmol
(1973) - et al.
The reproducibility of the intraocular pressure response to dexamethasone
Am J Ophthalmol
(1975) - et al.
The lack of toxicity of intravitreally administered triamcinolone acetonide
Am J Ophthalmol
(1981) - et al.
Experimental and clinical observations of the intraocular toxicity of commercial corticosteroid preparations
Am J Ophthalmol
(1986)
Intravitreal triamcinolone for refractory pseudophakic macular edema
Am J Ophthalmol
Fluocinolone acetonide sustained drug delivery device to treat severe uveitis
Ophthalmology
Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1
Arch Ophthalmol
The Lens Opacities Classification System (LOCS) III
Arch Ophthalmol
Cited by (0)
- ☆
Manuscript no. 220670.
- 1
The authors have no proprietary interest in this study.
- 2
Dr Audren, co–first author, contributed equally to the work.